Nektar Therapeutics Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 63

Employees

  • Stock Symbol
  • NKTR

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $37.27
  • (As of Friday Closing)

Nektar Therapeutics General Information

Description

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Contact Information

Website
www.nektar.com
Formerly Known As
Inhale Therapeutic Systems
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 455 Mission Bay Boulevard South
  • San Francisco, CA 94158
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 455 Mission Bay Boulevard South
  • San Francisco, CA 94158
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nektar Therapeutics Stock Performance

As of 13-Nov-2026, Nektar Therapeutics’s stock price is $37.27. Its current market cap is $1.28B with 34.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.27 $37.25 $33.40 - $109.00 $1.28B 34.2M 1.1M -$6.38

Nektar Therapeutics Financials Summary

As of 30-Sep-2026, Nektar Therapeutics has a trailing 12-month revenue of $52.2M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,461,403 681,749 35,313 (143,585)
Revenue 52,185 55,232 98,427 90,122
EBITDA (166,735) (138,715) (101,197) (262,116)
Net Income (177,256) (164,076) (118,961) (276,056)
Total Assets 1,037,251 280,406 303,850 398,033
Total Debt 73,881 85,751 102,564 117,776
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nektar Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nektar Therapeutics‘s full profile, request access.

Request a free trial

Nektar Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, Califo
Drug Discovery
San Francisco, CA
63 As of 2025

Bothell, WA
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nektar Therapeutics Competitors (97)

One of Nektar Therapeutics’s 97 competitors is Seagen, a Formerly VC-backed company based in Bothell, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA
Incyte Formerly VC-backed Wilmington, DE
Exelixis Formerly VC-backed Alameda, CA
Coherus Oncology Formerly VC-backed Redwood City, CA
Agenus Formerly VC-backed Lexington, MA
You’re viewing 5 of 97 competitors. Get the full list »

Nektar Therapeutics Patents

Nektar Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026064439-A1 Polymer engineered forms of colony stimulating factor-1 Pending 18-Sep-2024
WO-2025250701-A1 Anti-tumor necrosis factor receptor 2 (tnfr2) antibodies and methods of use Pending 28-May-2024
AU-2022414070-A1 Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions Pending 14-Dec-2021
CA-3239501-A1 Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions Pending 14-Dec-2021
EP-4447995-A1 Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions Pending 14-Dec-2021 A61K47/60
To view Nektar Therapeutics’s complete patent history, request access »

Nektar Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nektar Therapeutics Investments & Acquisitions (3)

Nektar Therapeutics’s most recent deal was a Early Stage VC with Pearl Therapeutics for . The deal was made on 01-Jul-2008.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pearl Therapeutics 01-Jul-2008 Early Stage VC Drug Discovery
Aerogen 20-Oct-2005 Merger/Acquisition Drug Delivery
Shearwater 01-Jun-2001 Merger/Acquisition Specialty Chemicals
To view Nektar Therapeutics’s complete investments and acquisitions history, request access »

Nektar Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

43.08 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Nektar Therapeutics’s complete esg history, request access »

Nektar Therapeutics Exits (1)

Nektar Therapeutics’s most recent exit was on 01-Jul-2008 from Pearl Therapeutics. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Pearl Therapeutics 01-Jul-2008 Completed
  • 3 buyers
To view Nektar Therapeutics’s complete exits history, request access »

Nektar Therapeutics FAQs

  • When was Nektar Therapeutics founded?

    Nektar Therapeutics was founded in 1990.

  • Where is Nektar Therapeutics headquartered?

    Nektar Therapeutics is headquartered in San Francisco, CA.

  • What is the size of Nektar Therapeutics?

    Nektar Therapeutics has 63 total employees.

  • What industry is Nektar Therapeutics in?

    Nektar Therapeutics’s primary industry is Drug Discovery.

  • Is Nektar Therapeutics a private or public company?

    Nektar Therapeutics is a Public company.

  • What is Nektar Therapeutics’s stock symbol?

    The ticker symbol for Nektar Therapeutics is NKTR.

  • What is the current stock price of Nektar Therapeutics?

    As of 13-Nov-2026 the stock price of Nektar Therapeutics is $37.27.

  • What is the current market cap of Nektar Therapeutics?

    The current market capitalization of Nektar Therapeutics is $1.28B.

  • What is Nektar Therapeutics’s current revenue?

    The trailing twelve month revenue for Nektar Therapeutics is $52.2M.

  • Who are Nektar Therapeutics’s competitors?

    Seagen, Incyte, Exelixis, Coherus Oncology, and Agenus are some of the 97 competitors of Nektar Therapeutics.

  • What is Nektar Therapeutics’s annual earnings per share (EPS)?

    Nektar Therapeutics’s EPS for 12 months was -$6.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process